Intellia Therapeutics Inc (NASDAQ:NTLA) rose 2.8% during trading on Friday . The stock traded as high as $18.38 and last traded at $18.37, with a volume of 72,386 shares traded. The stock had previously closed at $17.87.

Several research analysts have recently issued reports on the company. Credit Suisse Group AG assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price target for the company. Jefferies Group assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “hold” rating and a $33.00 price target for the company. Wedbush assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price target for the company. Leerink Swann assumed coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price target for the company. Finally, Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $35.50.

The stock’s market capitalization is $660.15 million. The firm’s 50-day moving average is $19.43 and its 200 day moving average is $23.16.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.